PMID- 28538193
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20180205
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 92
DP  - 2017 Aug
TI  - Ethyl pyruvate protects PC12 cells from oxygen-glucose deprivation: A potential 
      role in ischemic cerebrovascular disease.
PG  - 168-174
LID - S0753-3322(16)32084-4 [pii]
LID - 10.1016/j.biopha.2017.05.067 [doi]
AB  - The protective potential of ethyl pyruvate (EP) on neuron has been investigated 
      previously. This study was intended to investigate the effects of EP on the 
      severity of oxygen-glucose deprivation (OGD)-induced injury in neural-like PC12 
      cells. PC12 cells were exposed to OGD condition with or without EP treatment. 
      Then, cell viability, apoptosis, and the expressions of neurotrophic factors were 
      detected. Further, Sprague-Dawley rats were intravenously administered with 
      5mg/kg EP for 14 days post-middle cerebral artery occlusion (MCAO). The effects 
      of EP on the infarct volumes and neurological functions of MCAO rats were then 
      assessed. Result showed that EP alleviated OGD-diminished cells viability, 
      OGD-induced apoptosis, and OGD-reduced expressions of brain-derived neurotrophic 
      factor (BDNF), nerve growth factor (NGF) and Nestin in PC-12 cells. EP blocked 
      OGD-activated the Notch1 and nuclear factor Kappa B (NF-kappaB) signaling pathways in 
      PC12 cells. Besides, in vivo data demonstrated that EP treatment decreased 
      infarct volume and mNSS score, and increased the time spent on the rota-rod 
      apparatus of MCAO rats. To conclude, EP protected neural-like PC12 cells from 
      cerebral ischemia-reperfusion injury by suppressing apoptosis and promoting 
      neural restoration. Notch1 and NF-kappaB pathway might implicated in the functions of 
      EP on neuron.
CI  - Copyright (c) 2017 Elsevier Masson SAS. All rights reserved.
FAU - Li, Wenbo
AU  - Li W
AD  - Department of Neurology, Luoyang Central Hospital Affiliated to Zhengzhou 
      University, Luoyang 471009, Henan, China.
FAU - Lou, Jiyu
AU  - Lou J
AD  - Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450014, Henan, China. Electronic address: loujiyu339@126.com.
FAU - Wei, Liping
AU  - Wei L
AD  - Department of Neurology, Luoyang Central Hospital Affiliated to Zhengzhou 
      University, Luoyang 471009, Henan, China.
FAU - Bai, Hongying
AU  - Bai H
AD  - Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450014, Henan, China.
FAU - Zhang, Yaohui
AU  - Zhang Y
AD  - Department of Neurology, Luoyang Central Hospital Affiliated to Zhengzhou 
      University, Luoyang 471009, Henan, China.
FAU - He, Yuqing
AU  - He Y
AD  - Department of Neurology, Luoyang Central Hospital Affiliated to Zhengzhou 
      University, Luoyang 471009, Henan, China.
LA  - eng
PT  - Journal Article
DEP - 20170521
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Nestin)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Pyruvates)
RN  - 03O98E01OB (ethyl pyruvate)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
CIN - Biomed Pharmacother. 2018 Aug;104:849-850. PMID: 29566991
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Behavior, Animal/drug effects
MH  - Brain/*drug effects/metabolism/pathology
MH  - Brain Ischemia/*drug therapy/etiology/metabolism/pathology
MH  - Brain-Derived Neurotrophic Factor/agonists/genetics/metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Gene Expression Regulation/drug effects
MH  - Infarction, Middle Cerebral Artery/physiopathology
MH  - Injections, Intravenous
MH  - Male
MH  - Nerve Growth Factor/agonists/genetics/metabolism
MH  - Nerve Tissue Proteins/genetics/metabolism
MH  - Nestin/agonists/genetics/metabolism
MH  - Neurons/*drug effects/metabolism/pathology
MH  - Neuroprotective Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Pyruvates/administration & dosage/pharmacology/*therapeutic use
MH  - Random Allocation
MH  - Rats, Sprague-Dawley
MH  - Reperfusion Injury/*drug therapy/etiology/metabolism/pathology
MH  - Specific Pathogen-Free Organisms
OTO - NOTNLM
OT  - Apoptosis
OT  - Ethyl pyruvate
OT  - Ischemic cerebrovascular disease
OT  - Middle cerebral artery occlusion (MCAO)
OT  - Notch1/NF-kappaB pathway
OT  - Oxygen-glucose deprivation
EDAT- 2017/05/26 06:00
MHDA- 2018/02/06 06:00
CRDT- 2017/05/25 06:00
PHST- 2016/10/28 00:00 [received]
PHST- 2017/04/26 00:00 [revised]
PHST- 2017/05/12 00:00 [accepted]
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2017/05/25 06:00 [entrez]
AID - S0753-3322(16)32084-4 [pii]
AID - 10.1016/j.biopha.2017.05.067 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2017 Aug;92:168-174. doi: 10.1016/j.biopha.2017.05.067. Epub 
      2017 May 21.